TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20215539

Group type: EXPERIMENTAL
Intervention: Gene expression signature of 97 cell death genes
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: 6-gene expression signature derived from the 97-gene signature
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Homozygous deletions in genes
Number of subjects: 1058
Study: 18055007

Group type: EXPERIMENTAL
Intervention: Home-based, stage-matched multiple behavior interventions
Number of subjects: 1277
Study: 17459288

Group type: EXPERIMENTAL
Intervention: 5‐percent lactic acid mouthwash (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (distilled water mouthwash, group B)
Number of subjects: 70
Study: 12792007

Group type: EXPERIMENTAL
Intervention: Feedback reports combined with outreach visits from trained non‐physicians
Number of subjects: 185

Group type: COMPARATOR
Intervention: No special attention (control group)
Number of subjects: 185
Study: 10805362

Group type: EXPERIMENTAL
Intervention: Group 1 (N=58)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Group 2 (N=99)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Presence of vaginal white blood cells or mucopus
Number of subjects: 157
Study: 8870165

Group type: EXPERIMENTAL
Intervention: Intensive dietary lifestyle intervention (25% of total calories from fat)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: New enzyme immunoassay (EIA) for measurement of 2‐ and 16 alpha‐hydroxyestrone
Number of subjects: 174
Study: 1642580

Group type: EXPERIMENTAL
Intervention: Fixed mini-dose warfarin (1 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (to maintain INR of 2.0-4.0)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 200
Study: 6402612

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30690289

Group type: EXPERIMENTAL
Intervention: Short term life review intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Attention placebo (control group)
Number of subjects: 109
Study: 30431520

Group type: EXPERIMENTAL
Intervention: Active left DLPFC rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham left DLPFC rTMS
Number of subjects: 30
Study: 26581442

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 559

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 559
Study: 24554005

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2411

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2411
Study: 22243768

Group type: EXPERIMENTAL
Intervention: 6-millisecond pulse duration and 9 J/cm²
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.45-millisecond pulse duration and 6 J/cm²
Number of subjects: 20
Study: 20639632

Group type: EXPERIMENTAL
Intervention: L-carnitine (1,500 mg daily for 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment (control group, 31 patients)
Number of subjects: 29
Study: 18556425

Group type: EXPERIMENTAL
Intervention: SGLT‐IVTJ (subthreshold grid laser treatment combined with intravitreal triamcinolone injection)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SGLT (subthreshold grid laser treatment)
Number of subjects: 24
Study: 17851262

Group type: EXPERIMENTAL
Intervention: S-1 60 mg/body/day (level 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: S-1 80 mg/body/day (recommended dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: S-1 100 mg/body/day (level 3)
Number of subjects: 21
Study: 12802000

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 144
Study: 10733159

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of tetragastrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8934602

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations for ordinal data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative odds ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation methodology
Number of subjects: 0
Study: 1680573

Group type: EXPERIMENTAL
Intervention: Vecuronium 20, 30, or 40 micrograms.kg‐1
Number of subjects: 37
Study: 6185289

Group type: EXPERIMENTAL
Intervention: Tripotassium-dicitratobismuthate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29098393

Group type: EXPERIMENTAL
Intervention: DEX (1 μg/kg loading dose over 10 min, followed by 0.3-0.5 μg/kg/h continuous infusion)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 70
Study: 28132000

Group type: EXPERIMENTAL
Intervention: CCBT (Stressbusters)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Attention control (self-help websites)
Number of subjects: 91
Study: 25388882

Group type: EXPERIMENTAL
Intervention: HydraCoach(®) water bottle
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard education control group
Number of subjects: 32
Study: 23946732

Group type: EXPERIMENTAL
Intervention: Submucosal meperidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral meperidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 30
Study: 21248232

Group type: EXPERIMENTAL
Intervention: Nodule growth assessment by 9 radiologists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nodule presence assessment by 9 radiologists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Positive screening result assessment by 9 radiologists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Change in margins and attenuation assessment by 9 radiologists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up recommendations assessment by 9 radiologists
Number of subjects: 100
Study: 17433840

Group type: EXPERIMENTAL
Intervention: Add-on therapy with irbesartan (300 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (continuation of conventional therapy)
Number of subjects: 50
Study: 17038903

Group type: EXPERIMENTAL
Intervention: Endoscopic techniques
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Open donor nephrectomy
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Classic flank incision
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Open techniques
Number of subjects: 1450
Study: 14870620

Group type: EXPERIMENTAL
Intervention: Albendazole against hookworm and praziquantel against schistosomiasis
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1115
Study: 11572739

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study: 9420364

Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing (EMDR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting-list procedure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Same treatment without the eye movement
Number of subjects: 43
Study: 8499201

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study: 3087076

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (3 X 300 mg per day for 9 days as continuous intravenous infusion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31157716

Group type: EXPERIMENTAL
Intervention: PVR VT
Number of subjects: 150

Group type: COMPARATOR
Intervention: PVR-free VT
Number of subjects: 150
Study: 29326153

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCB)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 331
Study: 26212693

Group type: EXPERIMENTAL
Intervention: Calcium alginate packing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Carboxymethyl cellulose packing
Number of subjects: 27
Study: 24635772

Group type: EXPERIMENTAL
Intervention: 20% albumin and crystalloid solution
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Crystalloid solution alone
Number of subjects: 1818
Study: 23200687

Group type: EXPERIMENTAL
Intervention: Partners
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Women
Number of subjects: 1620
Study: 21518135

Group type: EXPERIMENTAL
Intervention: 1000 mg of metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1700 mg of metformin
Number of subjects: 60
Study: 19062610

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preventive or alleviating interventions
Number of subjects: 0
Study: 17003660

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Antidepressant medication (sertraline)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral therapy and antidepressant medication
Number of subjects: 73
Study: 14604304

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10952585

Group type: COMPARATOR
Intervention: Quinine (Q(7)) alone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Quinine (Q(7)) in combination with clindamycin (Q(7)C(7))
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Quinine (Q(7)) in combination with tetracycline (Q(7)T(7))
Number of subjects: 204
Study: 8831988

Group type: COMPARATOR
Intervention: Cyclophosphamide (CY) (4 g/m2) alone (group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (4 g/m2) with recombinant human granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) (5 micrograms/kg/day) (group II)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (4 g/m2) with rhGM‐CSF (group II)
Number of subjects: 15
Study: 1293274

Group type: EXPERIMENTAL
Intervention: Vibro-acoustic stimulation (VAS) for 5 sec at the beginning of one of the two 60 min FHR recordings
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control period (no VAS)
Number of subjects: 17
Study: 3515865

Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30293014

Group type: EXPERIMENTAL
Intervention: Moderate psychomotor agitation
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Severe psychomotor agitation
Number of subjects: 630

Group type: COMPARATOR
Intervention: Non-agitated patients
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Moderately agitated patients
Number of subjects: 630

Group type: COMPARATOR
Intervention: Severely agitated patients
Number of subjects: 630
Study: 27592734

Group type: EXPERIMENTAL
Intervention: Endovascular procedures
Number of subjects: 549

Group type: COMPARATOR
Intervention: Open procedures
Number of subjects: 549
Study: 24291168

Group type: EXPERIMENTAL
Intervention: LT patch (37.5 μg of ETEC LT)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: LT patch
Number of subjects: 2036
Study: 22588842

Group type: EXPERIMENTAL
Intervention: Group A (AF patients with pacemaker implantation)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Group B (patients with dual-chamber pacing)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison of Group A and Group B at follow-up
Number of subjects: 66
Study: 20865842

Group type: EXPERIMENTAL
Intervention: 3.75% imiquimod cream
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 247
Study: 18562771

Group type: EXPERIMENTAL
Intervention: High-protein, low-calorie diet with 3-g/day fish-oil supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 11
Study: 16311278

Group type: EXPERIMENTAL
Intervention: Bougie-guided technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Digital technique
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 120
Study: 12732415

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: non‐tobacco mint snuff
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: brand switching
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: elimination of ST use in specific situations
Number of subjects: 40
Study: 11126693

Group type: EXPERIMENTAL
Intervention: Novel anticancer agents targeting signal transduction and antiangiogenesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical cytotoxic agents
Number of subjects: 0
Study: 8834412

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 14
Study: 1483669

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate (EO)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate plus 1% polidocanol (EOP)
Number of subjects: 66
Study: 6437295

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol 10 minutes prior to exercise, in addition to theophylline (serum level 10-20 micrograms/ml)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of metaproterenol and cromolyn with theophylline
Number of subjects: 53
Study: 31868201

Group type: EXPERIMENTAL
Intervention: mLP formula (1.7 g protein/100 kcal)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CTRL formula (2.1 g protein/100 kcal)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mLP formula
Number of subjects: 90

Group type: COMPARATOR
Intervention: CTRL formula
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both formula groups
Number of subjects: 90
Study: 31870453

Group type: EXPERIMENTAL
Intervention: Hand hygiene champions' role in improving hand hygiene compliance through peer coaching and education.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Implementation strategies involving HH champions.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Traditional application of the implementation strategy for HH champions.
Number of subjects: 173
Study: 26884380

Group type: EXPERIMENTAL
Intervention: Usual care for conduct and substance use problems
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Baseline symptom severity
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Co-occurring developmental psychopathology characteristics
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Change over time in developmental psychopathology characteristics (peer delinquency, depression)
Number of subjects: 205
Study: 25198101

Group type: EXPERIMENTAL
Intervention: Expanded care coordinator (ECC) services including telephone calls at set intervals post-discharge (24 hours, 2, 4, 8, 12 weeks, 5, 7, 9 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 81
Study: 23647176

Group type: EXPERIMENTAL
Intervention: Social mindfulness (operationalized in a social decision-making paradigm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social mindfulness (socially mindful person)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social mindfulness (trustworthy faces)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social mindfulness (personality traits)
Number of subjects: 0
Study: 21385806

Group type: EXPERIMENTAL
Intervention: Weekly administration of low dose, high frequency ultrasound therapy (0.5 W/cm², 1 MHz, pulsed pattern of 1:4) for up to 12 weeks plus standard care
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Weekly administration of low dose, high frequency ultrasound therapy
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Baseline ulcer area
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Baseline ulcer duration
Number of subjects: 337
Study: 19092122

Group type: EXPERIMENTAL
Intervention: High-flux membranes
Number of subjects: 738

Group type: COMPARATOR
Intervention: Low-flux membranes
Number of subjects: 738
Study: 16418201

Group type: EXPERIMENTAL
Intervention: Manipulation package
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Usual general practice care
Number of subjects: 1334
Study: 12915774

Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 108
Study: 11206213

Group type: EXPERIMENTAL
Intervention: Tack box presented empty
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tack box presented full of tacks
Number of subjects: 3
Study: 9366940

Group type: EXPERIMENTAL
Intervention: Eltanolone (0.2 mg/kg in elderly, 0.3 mg/kg in young)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 113
Study: 1394027

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: RIMA compounds (including moclobemide)
Number of subjects: 0
Study: 4082604

Group type: EXPERIMENTAL
Intervention: Sport and Autogenic Training (AT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sport only
Number of subjects: 19
Study: 31941353

Group type: COMPARATOR
Intervention: Upright posture
Number of subjects: 81
Study: 30063150

Group type: EXPERIMENTAL
Intervention: Dental caries
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Dental caries with TDI and malocclusion
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1204
Study: 28348152

Group type: EXPERIMENTAL
Intervention: SAL200 (0.1, 0.3, 1, 3, and 10 mg/kg of body weight)
Number of subjects: 0
Study: 26153174

Group type: EXPERIMENTAL
Intervention: Recorded mothers' voices played for the newborns before and after blood sampling procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 24223034

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.2 mg nocte
Number of subjects: 55
Study: 22032706

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6080
Study: 18714152

Group type: EXPERIMENTAL
Intervention: L-carnitine 1 g orally 3 times a day for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17138063

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction therapy followed by FK506 monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional immunosuppression (FK506, mycophenolate mofetil and steroids) without any induction agent
Number of subjects: 0
Study: 14633147

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 25
Study: 10483579

Group type: EXPERIMENTAL
Intervention: 8 Mio. interferon beta‐1b subcutaneously every second day for two to three years
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo subcutaneously every second day for two to three years
Number of subjects: 718
Study: 8942591

Group type: EXPERIMENTAL
Intervention: Sitting position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lateral position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Number of subjects: 20
Study: 2017469

Group type: EXPERIMENTAL
Intervention: Insulin injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 7043116

Group type: EXPERIMENTAL
Intervention: Concurrent feedback from utilization review coordinators
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback or physician advisor involvement
Number of subjects: 0
Study: 31184207

Group type: EXPERIMENTAL
Intervention: Personalised medical scans
Number of subjects: 60

Group type: COMPARATOR
Intervention: Generic scans
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical illustrations
Number of subjects: 60
Study: 30785851

Group type: EXPERIMENTAL
Intervention: DPT‐IPV vaccine co‐administered with HRV vaccine
Number of subjects: 292

Group type: COMPARATOR
Intervention: DPT‐IPV vaccine staggered with HRV vaccine
Number of subjects: 292
Study: 30227610

Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA (2 g daily for three months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study: 26847975

Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment As Usual (TAU), n=8
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mindfulness-based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU), n=9
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) only, n=8
Number of subjects: 25
Study: 24989854

Group type: EXPERIMENTAL
Intervention: SST (Social Skills Training)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SST-PTI (Social Skills Training with Parent & Teacher Involvement)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 120
Study: 22285170

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacral colpopexy (LSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total vaginal mesh (TVM)
Number of subjects: 0
Study: 20808145

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 69
Study: 17620076

Group type: EXPERIMENTAL
Intervention: Grazax sublingual immunotherapy
Number of subjects: 934

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 934
Study: 16339217

Group type: EXPERIMENTAL
Intervention: General practitioner with special interest service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital outpatient care
Number of subjects: 0